The Supreme Court has once again blocked restrictions on mifepristone, allowing the abortion pill to continue flowing through telehealth prescriptions and mail delivery — but the legal battle is far from over, and the safety questions the Trump administration raised remain unanswered.
What the Supreme Court Actually Did
The Supreme Court issued an administrative stay blocking enforcement of a lower court ruling that would have restricted telehealth prescribing and mail delivery of mifepristone. [1] The stay is temporary, preserving the status quo while the case works through the courts. Critically, this is not a ruling on whether expanded access is medically justified or legally permanent — it is a procedural pause, not a victory declaration for either side.
This marks the latest chapter in a years-long legal fight over the drug. In 2024, the Supreme Court unanimously dismissed an earlier challenge — FDA v. Alliance for Hippocratic Medicine — but did so on standing grounds, meaning the Court never ruled on whether the FDA’s expanded access regime was actually safe or appropriate. [4] That merits question remains open, and the current litigation is pushing it back toward the courts.
How the Fight Reached This Point
The FDA first approved mifepristone in 2000, and the agency relaxed dispensing requirements in 2016 and again in 2021, ultimately allowing the drug to be prescribed via telehealth and shipped through the mail. [4] Those expansions dramatically widened access, removing in-person visit requirements that had previously applied. A federal appeals court later moved to reinstate restrictions on that expanded access, prompting the Supreme Court’s intervention to pause enforcement while the legal challenge proceeds. [1]
Louisiana was among the states that sought to reinstate in-person dispensing requirements while the appeal continued, directly tying the access question to state authority over abortion policy following the Supreme Court’s Dobbs decision. [2] That state-sovereignty angle matters — Dobbs returned abortion policy to the states, and mail delivery of abortion pills across state lines cuts directly against that framework, allowing patients in restrictive states to bypass laws their elected legislatures passed.
Trump Administration’s Safety Review Adds a New Dimension
The Trump administration asked courts to pause proceedings while the FDA conducted an internal safety review of mifepristone. [1] That request signals that the administration is not treating the drug’s expanded access regime as settled policy. While the request alone does not prove the drug is dangerous, it represents an on-record institutional acknowledgment that the regulatory framework governing mail and telehealth distribution deserves fresh scrutiny — scrutiny that was never completed under the Biden administration.
The Supreme Court on Thursday extended its administrative stay blocking enforcement of a lower court ruling that would have restricted access to the abortion pill mifepristone, allowing telehealth prescribing and mail distribution of the drug to continue https://t.co/Tw39Ym2ESn
— Jean (@Jeanneutral) May 14, 2026
What is notably absent from the public record is any comparative clinical data on whether mail delivery and telehealth prescribing produce worse patient outcomes than in-person dispensing. [2] Supporters of broad access point to the FDA’s long approval history, but the agency’s 2016 and 2021 rule relaxations have never been subjected to a full merits review by a federal court. Until that review happens — either through the FDA’s internal process or through the courts — the safety question is not settled. Conservative voters who believe Dobbs was correctly decided should watch this case closely: the outcome could determine whether state abortion laws can be effectively circumvented by a mailbox and a telehealth app.
Sources:
[1] Web – Supreme Court restores abortion pill access — for now – POLITICO
[2] Web – Supreme Court temporarily extends mifepristone access – STAT News
[4] Web – [PDF] 23-235 FDA v. Alliance for Hippocratic Medicine (06/13/2024)